



## Director/PDMR Shareholding

May 3, 2023 3:22 PM EDT

RNS Number : 3213Y  
MaxCyte, Inc.  
03 May 2023



**MaxCyte, Inc.**  
("MaxCyte" or the "Company")

### Exercise of options, PDMR dealing and Total Voting Rights

**Gaithersburg, Maryland - 3 May 2023:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 31 March 2023 and 12 April 2023, as per filings lodged with the SEC, Doug Doerfler, Chief Executive Officer, exercised options over 60,000 shares of common stock of \$0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 60,000 new shares of Common Stock issued pursuant to the Exercise, were sold by Doug Doerfler at a price range between of \$5.00 and \$5.03 per Common Stock ("Sale"). The sold shares represent approximately 1.6% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company. Following the Exercise, Doug Doerfler holds a further 3,293,680 options over Common Stock.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doug Doerfler on 18 November 2022 relating solely to the sale of shares acquired from exercise of an option that expires on 11 November 2024.

Additionally, the Company issued a further 86,154 of Common Stock to non-PDMR's pursuant to its block admission facility in satisfaction of the exercise of share options.

#### **Total voting rights**

The 146,154 new Common Stock have been admitted to trading on AIM pursuant to the Company's existing block admission facility. The new Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 103,050,899 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

**MaxCyte Contacts:**

**US IR Adviser**  
**Gilmartin Group**  
David Deuchler, CFA

+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

**Nominated Adviser and Joint  
Corporate Broker**  
Panmure Gordon  
Emma Earl / Freddy Crossley  
Corporate Broking  
Rupert Dearden

+44 (0)20 7886 2500

**UK IR Adviser**  
**Consilium Strategic  
Communications**  
Mary-Jane Elliott  
Chris Welsh

+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

### About MaxCyt

At MaxCyt, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [Twitter](https://twitter.com/maxcyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

### NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Doug Doerfler
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Cheif Executive Officer
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	MaxCyt Inc.
b)	LEI	54930053YHXULRFCU991
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument, type of instrument  Identification code	Common Stock of \$0.01 each  US57777K1060				
b)	Nature of the transaction	Exercise of Options over common stock				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>\$0.04</td> <td>60,000</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	\$0.04	60,000
Exercise Price(s)	Volume(s)					
\$0.04	60,000					
d)	Aggregated information  - Aggregated volume  - Price	n/a  n/a				
e)	Date of the transaction	31 March to 12 April 2023				
f)	Place of the transaction	USStock Exchange, Nasdaq				

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Doug Doerfler
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Cheif Executive Officer
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	MaxCyte Inc.
b)	LEI	54930053YHXULRFCU991
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument  Identification code	Common Stock of \$0.01 each  US57777K1060
b)	Nature of the transaction	Sale of common stock

c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>\$5.00</td> <td>24,568</td> </tr> <tr> <td>\$5.01</td> <td>100</td> </tr> <tr> <td>\$5.03</td> <td>35,332</td> </tr> </tbody> </table>		Exercise Price(s)	Volume(s)	\$5.00	24,568	\$5.01	100	\$5.03	35,332
		Exercise Price(s)	Volume(s)								
		\$5.00	24,568								
		\$5.01	100								
\$5.03	35,332										
d)	Aggregated information										
	- Aggregated volume	60,000									
	- Price	\$5.02									
e)	Date of the transaction	31 March to 12 April 2023									
f)	Place of the transaction	USStock Exchange, Nasdaq									

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEASSDEAFDEFA